As of 2025-09-18, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 74.38 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.1x - 17.7x | 15.9x |
| Forward P/E multiples | 14.1x - 18.8x | 17.2x |
| Fair Price | (13.00) - (16.33) | (15.25) |
| Upside | -245432.3% - -308256.5% | -287830.0% |
| Date | EV/EBITDA |
| 2025-09-11 | -0.22 |
| 2025-09-10 | -0.21 |
| 2025-09-09 | -0.22 |
| 2025-09-08 | -0.22 |
| 2025-09-05 | -0.22 |
| 2025-09-04 | -0.22 |
| 2025-09-03 | -0.22 |
| 2025-09-02 | -0.22 |
| 2025-08-29 | -0.22 |
| 2025-08-28 | -0.22 |
| 2025-08-27 | -0.22 |
| 2025-08-26 | -0.22 |
| 2025-08-25 | -0.22 |
| 2025-08-22 | -0.22 |
| 2025-08-21 | -0.22 |
| 2025-08-20 | -0.22 |
| 2025-08-19 | -0.21 |
| 2025-08-18 | -0.21 |
| 2025-08-15 | -0.21 |
| 2025-08-14 | -0.22 |
| 2025-08-13 | -0.21 |
| 2025-08-12 | -0.21 |
| 2025-08-11 | -0.21 |
| 2025-08-08 | -0.21 |
| 2025-08-07 | -0.21 |
| 2025-08-06 | -0.21 |
| 2025-08-05 | -0.22 |
| 2025-08-04 | -0.21 |
| 2025-08-01 | -0.21 |
| 2025-07-31 | -0.21 |
| 2025-07-30 | -0.21 |
| 2025-07-29 | -0.21 |
| 2025-07-28 | -0.22 |
| 2025-07-25 | -0.21 |
| 2025-07-24 | -0.21 |
| 2025-07-23 | -0.21 |
| 2025-07-22 | -0.21 |
| 2025-07-21 | -0.21 |
| 2025-07-18 | -0.21 |
| 2025-07-17 | -0.21 |
| 2025-07-16 | -0.22 |
| 2025-07-15 | -0.21 |
| 2025-07-14 | -0.21 |
| 2025-07-11 | -0.22 |
| 2025-07-10 | -0.21 |
| 2025-07-09 | -0.21 |
| 2025-07-08 | -0.21 |
| 2025-07-07 | -0.21 |
| 2025-07-03 | -0.21 |
| 2025-07-02 | -0.21 |